Immunity to COVID-19: Spike Protein Docking Site Is Achilles’ Heel of the Coronavirus

COVID-19 Achille's Heel

About 20% of COVID-19 survivors lack immunity against SARS-CoV-2, which depends on forming specific antibodies targeting the spike protein’s receptor binding domain (RBD). However, some cannot produce these antibodies for various reasons.

Around 20% of those who have recovered from COVID-19 fail to develop immune protection against SARS-CoV-2, according to a MedUni Vienna research team led by allergologist and immunologist Rudolf Valenta from the Center for Pathophysiology, Infectiology and Immunology. Their study found that the crucial immune protection that prevents the virus from docking and invasion of the body’s cells only occurs when a person is able to form specific antibodies against the folded receptor binding domain (RBD) of the spike protein. This docking site does not change significantly in with mutations of the virus. However, for various reasons, some people are unable to do this. An antigen-based vaccine targeting RBD could provide a solution, but such a vaccine is not yet available. The study was published in the leading journal Allergy.

A year ago, a research team led by study directors Rudolf Valenta and Winfried F. Pickl from MedUni Vienna’s Center for Pathophysiology, Infectiology and Immunology investigated the immune status of an initial cohort of patients who had recovered from a mild course of COVID-19. One of the findings at the time was that a significant proportion of infected patients were unable to form protective antibodies against SARS-CoV-2.

In the recently published follow-up study, Valenta and his team analyzed the antibody response of a larger cohort following mild and severe SARS-CoV-2 infection. The study used microarray (chip) technology developed at MedUni Vienna, in which a large number of viral antigens are applied to a microscopic chip by a robotic spotting machine. In addition, overlapping protein fragments (peptides) of these viral antigens were fixed to onto the chip, covering the entire spike protein on which the receptor binding domain (RBD) is located. This is the domain with which the SARS-CoV-2 virus binds to the ACE2 receptor of human cells.

The researchers expected to see an immune response to the peptides, but antibodies were exclusively formed against the intact, three-dimensionally folded spike protein. Proteins acquire their three-dimensional shape through the physically induced process of protein folding. It now appears that the SARS-CoV-2 virus needs the three-dimensionally folded protein to dock onto the body’s cells. Only an antibody response against the folded protein, but not against parts of it, protects against infection.

This leads to one major conclusion: high antibody levels against the folded spike protein, and especially against the RBD it contains, prevent the virus from binding to human cells. However, if someone is unable to form antibodies against the folded RBD, the person will not be well protected. The researchers also showed that only the folded RBD, but not unfolded RBD, generates immune protection upon immunization. Since the genetic vaccines currently in use mimic infection, it is possible that vaccination breakthroughs can may be explained by the failure to develop antibodies against folded RBD.

In summary, it can therefore be concluded that people who sufficiently form antibodies against folded RBD are protected against SARS-CoV-2 infections. These antibodies are readily measurable in the blood with neutralization tests. Unfortunately, 20% of those who have recovered from COVID-19 – and likely those who have been vaccinated – fail to produce these antibodies. Valenta explains: “We urgently need to develop an RBD-based antigen vaccine which is engineered to overcome the RBD non-responsiveness. This vaccine would be highly effective in inducing RBD-specific and thus neutralizing antibodies, whose levels could be kept high by booster vaccinations. In this way we could also exploit the “Achilles’ heel” of the virus, whose docking site does not change significantly with mutations, Valenta adds.

Reference: “Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes” by Pia Gattinger, Katarzyna Niespodziana, Karin Stiasny, Sabina Sahanic, Inna Tulaeva, Kristina Borochova, Yulia Dorofeeva, Thomas Schlederer, Thomas Sonnweber, Gerhard Hofer, Renata Kiss, Bernhard Kratzer, Doris Trapin, Peter A. Tauber, Arno Rottal, Ulrike Körmöczi, Melanie Feichter, Milena Weber, Margarete Focke-Tejkl, Judith Löffler-Ragg, Bernhard Mühl, Anna Kropfmüller, Walter Keller, Frank Stolz, Rainer Henning, Ivan Tancevski, Elisabeth Puchhammer-Stöckl, Winfried F. Pickl and Rudolf Valenta, 28 August 2021, Allergy.
DOI: 10.1111/all.15066

1 Comment on "Immunity to COVID-19: Spike Protein Docking Site Is Achilles’ Heel of the Coronavirus"

  1. Howard Jeffrey Bender, Ph.D. | September 16, 2021 at 12:11 pm | Reply

    Having the vaccines inhibit the binding site is great, but we all know that some of the virus will get through.

    All the coronaviruses and all their variants have different protein spikes, with Delta having one that’s more efficient at getting around the vaccines. But the real problem is in the virus itself, not its protein shell, and why the most dangerous (MERS, SARS, and Covid-19) are so infectious. My independent research has found multiple one-in-a-million nucleotide sequence matches between all the coronaviruses and the human genome. Those sequences are the same as some of the loops of human tRNA. Using those loops and their amino acid code matches, viruses may be able to fool the nucleus membrane in cells to allow the virus to enter and associate with the human DNA, creating more opportunities for further infection. Our immune system may be compromised and may no longer be able to stop the virus and other diseases from attacking organs throughout the body. Vaccines that attack the virus protein shells while ignoring their contents are doomed to failure from the Darwin effect, but recognizing these loops suggests a possible approach to successful coronavirus vaccines. Only the infection process is considered in my work, not the innate virulence of the virus. For more info, check out this YouTube, Coronavirus – Using Your DNA Against You. https://www.youtube.com/watch?v=8dOIzD6ch8s

Leave a Reply to Howard Jeffrey Bender, Ph.D. Cancel reply

Email address is optional. If provided, your email will not be published or shared.